Skip to main content

Modeling spontaneous Breast cancer metastasis TO the Bone with a first-of-its-kind 3D device that recapitulates physiological tissue-level complexity.

Objective

Cancer patients developing a metastatic disease are considered incurable. Breast cancer hits 1 woman in 8, and its most common metastatic site is the bone. A major hurdle to overcome breast cancer mortality is the lack of understanding of dynamics leading to the spread of breast cancer cells to the bone. Consequently, metastasis-suppressing agents have not been found to date, neither as newly developed drugs nor as repurposing of existing ones. The aim of the B2B device is to generate a first-of-a-kind 3D model of spontaneous breast cancer metastasis to the bone to dissect the complexity of the metastatic process and empower high-throughput drug screening in a physiological context. B2B will pursue its goal of developing a novel hybrid device able to 1) propagate patient-derived tumor organoids of clinically-relevant dimensions, with their own self-assembled micro-capillary networks, which are 2) continuously linked to a 3D bioprinted macro-vascular tree, organized in a hierarchical branched structure, connected in a closed circuit with 3) a vascularized marrow-containing bone ossicle, as the metastatic target. This is a unique approach, spanning the micro (single circulating metastatic cells, passing the endothelial barrier of capillary networks) to macro (tumor organoids and ossicles of clinically relevant size and tissue composition, connected by a hierarchically organized vascular tree) continuum to recapitulate spontaneous bone metastasis formation in breast cancer. This technology will transcend the limitations of current in vitro technologies, enabling physiological tissue-level complexity with organoids comprising several million cells, and its expected impact will be three-fold: to recapitulate the spontaneous metastatic process in breast cancer, to provide a breakthrough technology to investigate metastasis longitudinally and at the single cell level, and to lead to the identification of metastasis-suppressing therapies for breast cancer patients.

Call for proposal

H2020-FETOPEN-1-2016-2017
See other projects for this call

Coordinator

CONSIGLIO NAZIONALE DELLE RICERCHE
Address
Piazzale Aldo Moro 7
00185 Roma
Italy
Activity type
Research Organisations
EU contribution
€ 711 887,50

Participants (7)

UNIVERSITAT BASEL
Switzerland
EU contribution
€ 1 198 345
Address
Petersplatz 1
4051 Basel
Activity type
Higher or Secondary Education Establishments
UNIVERSITEIT MAASTRICHT
Netherlands
EU contribution
€ 464 383,75
Address
Minderbroedersberg 4
6200 MD Maastricht
Activity type
Higher or Secondary Education Establishments
CAMBRIDGE INNOVATION TECHNOLOGIES CONSULTING LIMITED
United Kingdom
EU contribution
€ 234 242,50
Address
St John's Innovation Centre Cowley Road
CB4 0WS Cambridge
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
REACT4LIFE SRL
Italy
EU contribution
€ 406 600
Address
Via Domenico Fiasella 1
16121 Genova
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
IN SRL
Italy
EU contribution
€ 230 587,50
Address
Via Carducci 9A
33100 Udine
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 390 825
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
BIOEMISSION TECHNOLOGY SOLUTIONS IKE
Greece
EU contribution
€ 162 500
Address
L. Mesogeion 387
153 43 Agia Paraskevi (Athina)
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)